S
Splice Bio
A biotech company based on intein technologies developed in the Muir Lab at Princeton University
About Splice Bio
Splice Bio is a biotechnology company that specializes in the development of gene therapies for genetic diseases. The company's approach is centered around its proprietary Protein Splicing platform, which is designed to overcome the size limitations of adeno-associated virus (AAV) vectors. This platform enables the delivery of large genes that would otherwise not fit into a single AAV, thereby expanding the range of diseases that can be targeted with gene therapy.
The company's business model is focused on the research and development of these novel gene therapies, with the ultimate goal of bringing them to market. Their primary clients are patients suffering from genetic diseases that are currently untreatable or have limited treatment options. Splice Bio operates in the highly specialized and regulated market of genetic medicine.
The company's lead program, SB-007, is an investigational gene therapy for the treatment of Stargardt disease, a rare genetic eye disorder that causes progressive vision loss. This indicates a focus on ophthalmology and rare diseases. The company likely generates revenue through partnerships, licensing agreements, and eventually, the sale of its approved therapies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Barcelona, Spain
- Employees
- 56
- Open positions
- None listed
- Dealroom signal
- 88.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, Woman Founder, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jun 2025 | $135M | $540M | Ysios Capital · NEA · Gilde Healthcare · Novartis Venture Fund | ↗ |
| SERIES AOther financing | Feb 2022 | $55M | $220M | NEA · Gilde Healthcare · Novartis Venture Fund · Asabys Partners | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Splice Bio is 7.3K monthly website visits, up 15.9% over the last three months. Splice Bio's team grew 5.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
Caixa Capital Risc
Criteria Venture Tech
Ysios Capital
Asabys Partners
UCB Ventures
NEA
Gilde Healthcare
Novartis Venture Fund
Sanofi Ventures
EQT Life Sciences
Roche Venture Fund
Other known investors2 additional known investors
Princeton University
University of Barcelona
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Splice Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Splice Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.